PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

Other companies with checkpoint inhibitors on the market also have HCC in its sights, including Merck KGaA/Pfizer whose Bavencio (avelumab) PD-L1 inhibitor is in phase II testing in this indication.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Meanwhile, Lilly and Innovent are running upwards of 20 studies as they play catch-up with other PD-1/PD-L1 drugs testing the drug in other indications, including kidney, liver, colorectal ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

who won yesterday test match The commercialization of PD-L1 products is just around the corner. Alphamab Oncology's performance on the Hong Kong Stock Exchange boosts market confidence The number of ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the ...